logo

For the Inventor, By the Inventor

The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 9758520 B1

PDFFull Text
Date of Patent:
Sep. 12, 2017

Filed:

Oct. 03, 2016

Substituted fused heterocycles as gpr119 modulators for the treatment of diabetes, obesity, dyslipidemia and related disorders

Applicant:

Sanofi, Paris, FR;

Inventors:

Lothar Schwink, Frankfurt am Main, DE;

Christian Buning, Frankfurt am Main, DE;

Heiner Glombik, Frankfurt am Main, DE;

Matthias Gossel, Frankfurt am Main, DE;

Dieter Kadereit, Frankfurt am Main, DE;

Nis Halland, Frankfurt am Main, DE;

Matthias Lohmann, Frankfurt am Main, DE;

Christoph Pöverlein, Frankfurt am Main, DE;

Kurt Ritter, Frankfurt am Main, DE;

Assignee:

SANOFI, Paris, FR;

Attorney:

Morrison & Foerster LLP

Primary Examiner:

Niloofar Rahmani

Int. Cl.
CPC ...
C07D 401/02 (2006.01); C07D 401/10 (2006.01); C07D 401/14 (2006.01); A61K 31/437 (2006.01); A61K 31/4353 (2006.01); C07D 471/04 (2006.01); C07D 231/56 (2006.01); C07D 249/18 (2006.01); A61K 45/06 (2006.01); A61K 31/4439 (2006.01); A61K 31/155 (2006.01); A61K 31/397 (2006.01); A61K 31/40 (2006.01); A61K 31/444 (2006.01); A61K 31/702 (2006.01);
U.S. Cl.
CPC ...
C07D 471/04 (2013.01); A61K 31/155 (2013.01); A61K 31/397 (2013.01); A61K 31/40 (2013.01); A61K 31/444 (2013.01); A61K 31/4439 (2013.01); A61K 31/702 (2013.01); A61K 45/06 (2013.01); C07D 231/56 (2013.01); C07D 249/18 (2013.01); C07D 401/14 (2013.01);
Abstract

The present invention relates to substituted fused heterocyclic compounds. The substituted fused heterocyclic compounds are GPR119 modulators and useful for the prevention and/or treatment of diabetes, obesity, dyslipidemia and related disorders. The invention furthermore relates to the use of substituted fused heterocyclic compounds as active ingredients in pharmaceuticals, and pharmaceutical compositions comprising them.

Find Patent Forward Citations

Loading…